Skip to main content
Publications
Rebordosa C , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia-Esteban R , Plana E , Tormos A , Farsani SF, Perez-Gutthann S , Pladevall-Vila M . Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts . Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Winfree KB, Ainsworth C, Njue A , Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A , Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review . Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671
Herman WH, Hoerger TJ, Hicks K , Brandle M, Sorensen SW, Zhang P, Engelgau MM, Hamman RF, Marrero DG, Ackermann DT, Ratner RE. Managing people at high risk for diabetes . Ann Intern Med. 2006 Jan 3;144(1):66-7.